Ken Griffin Monte Rosa Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,300 shares of GLUE stock, worth $63,036. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,300
Previous 43,800
65.07%
Holding current value
$63,036
Previous $247,000
56.68%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding GLUE
# of Institutions
71Shares Held
34.5MCall Options Held
80.3KPut Options Held
12.6K-
Nea Management Company, LLC Timonium, MD7.69MShares$31.7 Million3.81% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.1MShares$21 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$20.3 Million0.44% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.54MShares$18.7 Million0.39% of portfolio
-
Black Rock Inc. New York, NY2.31MShares$9.5 Million0.0% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $192M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...